Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation

Blood Coagul Fibrinolysis. 2003 Jan;14(1):77-8. doi: 10.1097/00001721-200301000-00013.

Abstract

Bupropion hydrochloride is an effective drug for people who want stop smoking, and its use has recently increased in many countries. The main side effects of this drug are related to its dopaminergic activity and are dose dependent. To date, no cases of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) have been reported in literature. Here we describe a case of a woman who developed a sporadic form of TTP-HUS during a treatment with bupropion for smoking cessation, successfully treated with plasma ex-change therapy. The authors wish to make readers aware of bupropion as a possible cause of this potentially lethal disease.

Publication types

  • Case Reports

MeSH terms

  • Bupropion / adverse effects*
  • Female
  • Hemolytic-Uremic Syndrome / chemically induced*
  • Hemolytic-Uremic Syndrome / etiology
  • Hemolytic-Uremic Syndrome / therapy
  • Humans
  • Middle Aged
  • Plasma Exchange
  • Purpura, Thrombotic Thrombocytopenic / chemically induced*
  • Purpura, Thrombotic Thrombocytopenic / etiology
  • Purpura, Thrombotic Thrombocytopenic / therapy
  • Smoking / drug therapy

Substances

  • Bupropion